Volitionrx Ltd Cash Flow Conversion Efficiency
Volitionrx Ltd cash flow conversion efficiency. Based on the latest financial reports, Volitionrx Ltd (VNRX) has a cash flow conversion efficiency ratio of 0.154x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.49 Million) by net assets ($-35.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Volitionrx Ltd (2004–2025)
Cash flow conversion efficiency of Volitionrx Ltd from 2004 to 2025. This chart illustrates how Volitionrx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VNRX stock price for real-time trading data and today's change.
Volitionrx Ltd Cash Flow Conversion Ratio Explained
Volitionrx Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Volitionrx Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Volitionrx Ltd ranked by their cash flow conversion efficiency. Also see market value of Volitionrx Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Skycorp Solar Group Limited Ordinary Shares
NASDAQ:PN
|
-0.035x |
|
TEAM PLC
F:1WQ
|
N/A |
|
Brill Shoe Industries Ltd
TA:BRIL
|
0.383x |
|
SSP Group PLC
LSE:SSPG
|
1.962x |
|
Stern Groep N.V.
AS:PBH
|
0.712x |
|
DAIHAN Scientific Co. Ltd
KQ:131220
|
0.006x |
|
KebNi AB (publ)
ST:KEBNI-B
|
0.158x |
|
Libet S.A.
WAR:LBT
|
-0.036x |
Annual Cash Flow Conversion Efficiency for Volitionrx Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Volitionrx Ltd from 2004 to 2025. Review Volitionrx Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-35.59 Million | $-19.68 Million | 0.553x | -44.24% |
| 2024-12-31 | $-26.11 Million | $-25.89 Million | 0.992x | -52.16% |
| 2023-12-31 | $-8.71 Million | $-18.06 Million | 2.073x | -57.56% |
| 2022-12-31 | $-3.13 Million | $-15.28 Million | 4.886x | +515.21% |
| 2021-12-31 | $17.72 Million | $-20.85 Million | -1.177x | -16.45% |
| 2020-12-31 | $16.29 Million | $-16.46 Million | -1.010x | -12.62% |
| 2019-12-31 | $14.20 Million | $-12.74 Million | -0.897x | +26.07% |
| 2018-12-31 | $12.14 Million | $-14.73 Million | -1.214x | +0.89% |
| 2017-12-31 | $9.96 Million | $-12.19 Million | -1.224x | -186.32% |
| 2016-12-31 | $21.18 Million | $-9.06 Million | -0.428x | +70.51% |
| 2015-12-31 | $6.04 Million | $-8.77 Million | -1.450x | +87.10% |
| 2014-12-31 | $368.18K | $-4.14 Million | -11.247x | -148.21% |
| 2013-12-31 | $680.67K | $-3.08 Million | -4.531x | -63.23% |
| 2012-12-31 | $833.79K | $-2.31 Million | -2.776x | -79.29% |
| 2011-12-31 | $1.09 Million | $-1.69 Million | -1.548x | -3905.47% |
| 2010-12-31 | $-114.29K | $-4.65K | 0.041x | -23.90% |
| 2009-12-31 | $-107.54K | $-5.75K | 0.053x | +112.84% |
| 2008-12-31 | $-95.92K | $39.95K | -0.416x | -288.41% |
| 2007-12-31 | $-78.32K | $-17.31K | 0.221x | -75.14% |
| 2006-12-31 | $-56.23K | $-50.00K | 0.889x | +185417.27% |
| 2005-12-31 | $-72.94K | $35.00 | 0.000x | -148.77% |
| 2004-12-31 | $-64.03K | $-63.00 | 0.001x | -- |
About Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleos… Read more